Organon (OGN) Income from Continuing Operations (2020 - 2026)
Organon (OGN) posted quarterly Income from Continuing Operations of 108000000.0 for Q2 2026, down 25.52% year-over-year from 145000000.0 in Q2 2025, and down 26.03% on a QoQ basis from 146000000.0 in Q1 2026.
Organon (OGN) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Organon has reported Income from Continuing Operations for 7 years, with the latest figure at 108000000.0 in Q2 2026.
- Income from Continuing Operations for Q2 2026 came in at 108000000.0, down 25.52% year-over-year; the trailing twelve-month figure through Jun 2026 was 209000000.0 (down 70.14% YoY), and the FY2025 annual result was 187000000.0, down 78.36% from the prior year.
- Income from Continuing Operations eased to 108000000.0 in Q2 2026, from 146000000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 546000000.0 in Q4 2023 and troughed at 205000000.0 in Q4 2025.
- A 5-year average of 203611111.11 and a median of 186000000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The widest annual swing landed in 2024, when Income from Continuing Operations jumped 518.97%; it then plunged 288.07% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 528000000.0 in 2022, then rose by 3.41% to 546000000.0 in 2023, then sank by 80.04% to 109000000.0 in 2024, then plunged by 288.07% to 205000000.0 in 2025, then surged by 152.68% to 108000000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 108000000.0 in Q2 2026, 146000000.0 in Q1 2026, and 205000000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | 108.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.00 Mn |
| Mar 31, 2026 | 146.00 Mn |
| Dec 31, 2025 | -205.00 Mn |
| Sep 30, 2025 | 160.00 Mn |
| Jun 30, 2025 | 145.00 Mn |
| Mar 31, 2025 | 87.00 Mn |
| Dec 31, 2024 | 109.00 Mn |
| Sep 30, 2024 | 359.00 Mn |
| Jun 30, 2024 | 195.00 Mn |
| Mar 31, 2024 | 201.00 Mn |
| Dec 31, 2023 | 546.00 Mn |
| Sep 30, 2023 | 58.00 Mn |
| Jun 30, 2023 | 242.00 Mn |
| Mar 31, 2023 | 177.00 Mn |
| Dec 31, 2022 | 766.00 Mn |
| Sep 30, 2022 | 227.00 Mn |
| Jun 30, 2022 | 234.00 Mn |
| Mar 31, 2022 | 348.00 Mn |
| Dec 31, 2021 | 202.00 Mn |
| Sep 30, 2021 | 323.00 Mn |